A Rude, But Needed, Awakening For Biotech
Markets giveth. Markets taketh away. So goes the shakeout in biotechnology. But while it's easy to mope about what went wrong--"avaricious" venture capitalists, naive entrepreneurs, ill-advised testing shortcuts--the reality is that the impending consolidation is the best strategy for the long-term health of this still-promising industry.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.